LGC reports half year trading in line with expectations

News (ZH) - Update for the half year ended 30 September 2021

LGC publishes ESG report for 2020-21

News (ZH) - LGC's first ESG report using GRI Standards, the most widely used sustainability reporting framework 

LGC to develop new Berlin site to expand Nucleic Acid Therapeutics capacity

News (ZH) - Site will be dedicated to medium to large scale and early to late Phase Clinical GMP manufacturing of Nucleic Acid Therapeutics

LGC’s commitment to carbon net zero

News (ZH) - LGC is committing to being carbon net zero by 2050

LGC, Biosearch Technologies testing workflow underpins expansion of COVID-19 testing in New York

News (ZH) - Nexar workflow continues to enable simple, scalable, and cost-effective testing 

Measurement science improves standardisation of SARS-CoV-2 quantification

News (ZH) - NML team analysis vital to understanding potential discrepancies in measured viral burden used to manage CoVid-19 pandemic

LGC launches SARS-CoV-2 Delta Variant quality solution

News (ZH) - Safe, non-infectious, and replication deficient quality solution for Delta variant detection and analysis

Euan O’Sullivan appointed CEO of LGC

News (ZH) - Euan succeeds Tim Robinson, who will become Chairman of LGC

NML responds to the 2021 UK Innovation Strategy

News (ZH) - We particularly welcome the recognition of the world-leading status of the UKs Public Sector Research Establishments (PSREs) and other publicly funded research institutes such as ours and the increased role these will play in catalysing and supporting innovations with significant local economic and societal impacts.

LGC welcomes new senior appointment 

News (ZH) - Judy Lewent joins Board as Non-Executive Director